Illumina, Inc.
Illumina Announces Strong Q1 2026 Financial Results and New Share Repurchase Program
Summary
Illumina, Inc. reported strong financial results for the first quarter of fiscal year 2026, with revenue of $1.09 billion, up 4.8% from Q1 2025. The company achieved a GAAP operating margin of 19.2% and a non-GAAP operating margin of 21.9%. GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.15. On April 28, 2026, the Board of Directors authorized a new share repurchase program for up to $1.5 billion of the Company's common stock, in addition to the existing $1.5 billion program from August 2024.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement